Eocene (NASDAQ: EOCN) announced its subsidiary Colospan's first European commercial distribution agreement for CG-100, granting Hospital Line exclusive rights in Greece and Cyprus.
The agreement covers marketing, sales and distribution and includes mutually agreed commercial targets. Colospan expects the planned launch in both countries to proceed alongside its ongoing U.S. pivotal study. The company intends the agreement to support potential expansion into additional European markets. The agreement currently covers only CG-100; additional products may be added as they become commercially available. CG-100 is a device intended to protect surgical connections in the colon or rectum and reduce the need for diverting stomas, which redirect bowel contents.